Home › Peripheral Arterial Disease › North Carolina › Charlotte
Peripheral Arterial Disease clinical trials in Charlotte, NC
3 studies for Peripheral Arterial Disease are looking for participants at sites in and around Charlotte (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- Metrolina Nephrology Associates, PA, Charlotte
Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.
Recruiting
- Monroe Biomedical Research, Monroe · 24 mi away
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
Recruiting
- Atrium Health, Charlotte
About Peripheral Arterial Disease
Peripheral arterial disease (PAD) happens when there is a narrowing of the blood vessels outside of your heart. Learn about symptoms and treatment.
More about Peripheral Arterial Disease on MedlinePlus
Peripheral Arterial Disease trials in other cities
- Boston, MA10 studies
- Dallas, TX9 studies
- Cleveland, OH9 studies
- Chicago, IL9 studies
- Houston, TX8 studies
- Omaha, NE7 studies
- Gainesville, FL7 studies
- Minneapolis, MN6 studies
- Nashville, TN6 studies
- Miami, FL6 studies
- Detroit, MI6 studies
- Aurora, CO6 studies
Other studies in Charlotte
- Cancer (all types)27 studies
- Breast Cancer22 studies
- Multiple Myeloma21 studies
- Non-Small Cell Lung Cancer19 studies
- Acute Myeloid Leukemia16 studies
- Obesity16 studies
- Overweight15 studies
- Colorectal Cancer13 studies
- Ovarian Cancer12 studies
- Heart Failure11 studies
- Metastatic Cancer11 studies
- Head and Neck Squamous Cell Carcinoma10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.